171 related articles for article (PubMed ID: 31435033)
21. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI; McMillan A; Negrin RS; Horning SJ; Laport GG
Biol Blood Marrow Transplant; 2008 Jul; 14(7):741-7. PubMed ID: 18541192
[TBL] [Abstract][Full Text] [Related]
23. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China.
Xie Y; Wang X; Leng X; Zheng W; Ping L; Zhang C; Liu W; Deng L; Wu M; Song Y; Zhu J
Ann Hematol; 2020 Mar; 99(3):549-555. PubMed ID: 31980860
[TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
27. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
28. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
[TBL] [Abstract][Full Text] [Related]
29. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T
Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
31. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
32. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
[TBL] [Abstract][Full Text] [Related]
33. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
[No Abstract] [Full Text] [Related]
35. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
37. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
[TBL] [Abstract][Full Text] [Related]
38. Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
Fakhri B; Yilmaz E; Gao F; Ambinder RF; Jones R; Bartlett NL; Cashen A; Wagner-Johnston N
Leuk Lymphoma; 2021 Oct; 62(10):2408-2415. PubMed ID: 33988071
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study.
Paviglianiti A; Tozatto Maio K; Rocha V; Gehlkopf E; Milpied N; Esquirol A; Chevallier P; Blaise D; Gac AC; Leblond V; Cahn JY; Abecasis M; Zuckerman T; Schouten H; Gurman G; Rubio MT; Beguin Y; Corral LL; Nagler A; Snowden JA; Koc Y; Mordini N; Bonifazi F; Volt F; Kenzey C; Robinson SP; Montoto S; Gluckman E; Ruggeri A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2265-2270. PubMed ID: 30031070
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
